VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. The early in vitro studies showed that an AOC candidate combining the companies' technologies exhibited greater potency than the equivalent unconjugated oligonucleotide, suggesting the approach's potential for selectively delivering therapeutic oligonucleotides to disease-specific cells.
This collaboration leverages VERAXA's proprietary click chemistry-powered conjugation technology, which the company notes demonstrates its applicability beyond its primary focus on solid tumors. The companies are currently discussing next steps in the collaboration, indicating the promising nature of the findings. The ability to deliver oligonucleotides specifically to target cells could significantly improve therapeutic efficacy while reducing off-target effects, a critical consideration in treating chronic immune conditions.
The positive early results underscore the potential of AOCs as a new class of therapeutics. By conjugating oligonucleotides to antibodies, the approach aims to harness the specificity of antibodies to deliver these therapeutic agents directly to the cells involved in disease processes. This could lead to more effective treatments with fewer side effects compared to conventional oligonucleotide therapies, which often suffer from poor cellular uptake and nonspecific distribution.
For VERAXA, this collaboration highlights the versatility of its technology platform, which is already being advanced in clinical development for solid tumors through its pipeline of antibody-drug conjugates (ADCs) and proprietary BiTAC formats. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL) and is building a premier engine for next-generation antibody-based therapeutics.
Secarna Pharmaceuticals brings its expertise in oligonucleotide development to the partnership. The combined strengths of both companies are expected to accelerate the development of AOC candidates, potentially addressing unmet medical needs in autoimmune and chronic immune diseases. These conditions often require long-term management, and targeted therapies could offer improved outcomes and quality of life for patients.
The announcement is a significant step forward in the field of targeted therapeutics. As research progresses, the success of this collaboration could pave the way for broader applications of AOCs in other disease areas. Both companies are committed to advancing the science and are evaluating the next phases of their collaboration to bring these potential therapies closer to clinical testing.
For more information on VERAXA Biotech and its pipeline, visit the company's newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/IF9Cy.
